Astellas Expansion Of Domestic Sales Impressive Despite NHI Pricing; Launches Mycamine in U.K.
This article was originally published in PharmAsia News
Executive Summary
TOKYO - Astellas' Japanese domestic sales expanded 4.5 percent compared to last year, which analysts said were impressive because of the lowering of the National Health Insurance pricing across the board in April. The company attributed the increase to sales of long-acting angiotensin-II receptor antagonist Micardis (telmisartan), the hypnotic Myslee, and a few other products